Duaer

Guides

2027 Pharmacovigilance AI Tools: How to Vet Vendors Before You Sign

Drawn from the Duaer documentation site, this article explains why choosing pharmacovigilance AI tools is a risk decision rather than a feature comparison, and offers practical guidance on building test sets, reviewing contracts, and monitoring post-deployment metrics.

Why Vendor Selection Is Harder in Pharmacovigilance

Safety teams receive a steady stream of AI product pitches, and the demos are often convincing. The intake interface reads case narratives, suggests MedDRA terms, flags possible duplicate reports, and drafts follow-up letters. The problems tend to surface after the contract is signed. Real case intake is messy: narratives arrive in several languages, dates are incomplete, the same event may be reported by three different reporters, and a follow-up can change the seriousness assessment. A tool that performs flawlessly on a vendor's curated sample can quietly mistriage the cases that matter most. AI is not useless in pharmacovigilance. The trouble is that purchasing decisions are often treated as feature comparisons when they are really risk decisions.

Most departments can tolerate an imperfect tool, but safety reporting cannot. Under the frameworks that apply in major markets, the marketing authorization holder remains responsible for adverse event reporting, regardless of which vendor's software touched the case. If a tool misses a serious case or codes an event inconsistently, the accountability sits with your company, not the vendor.

This means you are not buying a faster form. You are buying a component of a controlled process that must be validated, documented, and explainable to an inspector. A useful early question is this: if an auditor asks why a case was judged non-serious, can your team reconstruct the reasoning, including what the AI suggested and who overrode it?

Common Purchasing Mistakes

The first mistake is buying by feature checklist. Automated coding, signal detection dashboards, and literature screening all sound valuable, but they sit at different points in the workflow and carry very different risk. Using AI to pre-screen literature with human review is far safer than letting a model make causality or seriousness judgments without oversight.

The second mistake is accepting a vendor's accuracy claims without running your own tests. Published accuracy describes performance on the vendor's data, not on your reporters, languages, and product portfolio.

The third mistake is ignoring the audit trail. Many teams stop once they confirm that a tool has logging. What is actually needed is a record of model inputs, outputs, version numbers, reviewer identity, and every human override. Without these, even a fast tool will not survive an audit. For guidance on what to check in practice, see the AI Audit Logs Guide.

The fourth mistake is assuming the vendor owns validation. Vendors can supply documentation, but your organization must still validate the tool in your own environment for its intended use.

What a Sound Evaluation Looks Like

Start by mapping your own workflow rather than adopting the vendor's flowchart. A typical chain includes case intake and duplicate detection, seriousness and expectedness triage, case processing and coding, literature monitoring, signal detection, and periodic aggregate reporting. Label each step with its risk level and the human review checkpoints that already exist. This map becomes the basis for every conversation with a vendor.

Next, choose one or two steps for a first pilot. Duplicate detection and literature screening are usually lower risk because errors are relatively visible and reviewers can catch them. Autonomous causality assessment is a poor first step because its errors are often hidden and their consequences are serious. During the pilot, a person should make the final decision on every reportable case.

Then build a test set from your own historical cases. Include routine cases, but deliberately add difficult ones: narratives in languages other than English, reports with missing dates, multi-drug exposures, near-duplicate reports from different sources, and cases that were reclassified after follow-up. Send the same blinded test set to each shortlisted vendor, ask them to run it live under your configuration, and record every output.

A practical way to organize this work is to treat the evaluation as a workflow rather than a spreadsheet of vendor claims. For example, Duaer is a platform where teams can set up step-by-step testing and review records, which makes it easier to compare candidate solutions within the same process. Whichever product you use, judge it on your own test set, not on its marketing materials.

Contract and Governance Checks Before Signing

Before signing, confirm five things. First, the audit trail must cover every case, including the AI recommendation, any human override, and the model version. Second, you need to know where case data is processed and which subprocessors will access it, which matters for privacy obligations and cross-border safety data exchange. Third, the vendor must commit to notifying you of model changes and to a revalidation step before any new version goes into production. Fourth, you should be able to export your case data and logs in a usable format if you later change vendors. Fifth, the pilot scope should be written down, including what the tool may decide and what it may not.

If you need a broader checklist covering common gaps across industries, see the AI Vendor Evaluation Checklist.

After Go-Live, Measure What Matters

Do not measure success only by time saved. Track rework rates in coding and triage, reviewer override rates by category, missed duplicates found in later quality checks, on-time reporting against internal deadlines, and findings from internal audits. A tool that saves time but raises override rates or lets duplicates slip through is not a success. Set these baselines before the pilot begins, or you will have nothing to compare against.

One Thing You Can Do This Week

Write your current case intake process as six to eight steps, and mark the one where errors are most easily missed. Pull at least one hundred historical cases for that step and deliberately include the hard ones. Then send the same blinded test set to two vendors and ask for live results with logs. The outputs will tell you more than any demo.

If you want to run this kind of step-by-step evaluation in one organized workflow, you can sign up for a trial at https://www.duaer.com. Use it to test your own cases and judge results against your own data.

If you tell us your specific scenario, we can send back a written adoption roadmap. Link: https://api.duaer.com/form/c59a907a-3697-4edf-a04d-3ea0fb72fdc8

In pharmacovigilance, the best AI tool is one whose errors you can see, explain, and correct before an inspector finds them.

Questions

Does AI-assisted seriousness assessment in pharmacovigilance still require human review?

Yes. The marketing authorization holder remains responsible for adverse event reporting no matter which vendor's software was involved. During a pilot, a person should make the final decision on every reportable case, AI recommendations should be recorded, and any human override should leave a trace.

How many historical cases should I use to test an AI tool before signing?

The source recommends preparing at least about one hundred historical cases, deliberately including hard examples such as non-English narratives, missing dates, multi-drug exposures, near-duplicates, and cases reclassified after follow-up. Use the same blinded dataset for every vendor, have each run it live under your configuration, and keep the logs.

How do I tell whether a pharmacovigilance AI tool is worth keeping long term?

Do not look at time saved alone. Set baselines before the pilot and keep tracking rework rates, reviewer override rates by category, duplicates missed in later quality checks, reporting timeliness, and internal audit results. If time savings come with higher override rates or more missed cases, the tool is not delivering real value.